• RESTRICT-seq Maps Epigenetic SCC Resistance

  2026-09-30

  The preprint introduces RESTRICT-seq, a time-gated CRISPR screening strategy designed to distinguish epigenetic dependencies that arise during squamous cell carcinoma resistance from vulnerabilities present before resistance develops. Its main contribution is methodological: aligning genetic perturbation with disease-state timing provides a more informative framework for discovering resistance-associated dependencies and prioritizing follow-up experiments.

• Rocilinostat (ACY-1215): Workflow Guide

  2026-09-29

  Build cleaner HDAC6-centered experiments with Rocilinostat (ACY-1215), from α-tubulin acetylation and multiple myeloma cell viability assays to proteasome-inhibitor combination studies. A separate neurodevelopment application shows how the compound can support carefully bounded cilia and neural-progenitor hypotheses without overstating cross-domain evidence.

• Tiamulin Workflows for Veterinary Research

  2026-09-29

  Tiamulin (Thiamutilin) combines pleuromutilin antibacterial activity with investigational anti-inflammatory effects, making it useful for susceptibility, cell-signaling, and pharmacokinetic workflows. This guide translates those properties into practical assay design, formulation controls, PK/PD interpretation, and troubleshooting for veterinary research.

• hCG–EZH2–CXCL10 Signaling in Human Decidua

  2026-09-28

  The reference study shows that human chorionic gonadotropin suppresses CXCL10 in human decidual stromal cells through EZH2-dependent deposition of the repressive H3K27me3 mark. By connecting hormone signaling, promoter-localized chromatin remodeling, and CD8-cell recruitment, the work provides a mechanistic framework for understanding immune regulation at the maternal–fetal interface.

• From SIRT1 Biology to Bone-Regeneration Strategy

  2026-09-28

  A translational perspective on how SIRT1 links vascular and osteogenic function in aging bone—and how researchers can rigorously evaluate SRT1720 HCl as a tool for testing that biology.

• SP2509 and LSD1: Interpreting Epigenetic Dependencies

  2026-09-27

  SP2509 is a potent Lysine-specific demethylase 1 antagonist for studying how LSD1-linked chromatin regulation shapes cancer-cell states. This article connects its AML evidence to a breast-cancer study of BRD4–RAC1 co-targeting while clarifying what that cross-domain comparison can—and cannot—tell researchers.

• Dual-SMAD and Wnt Inhibition for iPSC-Derived RGCs

  2026-09-26

  The study presents a chemically defined strategy combining SMAD-pathway and canonical Wnt inhibition to generate retinal ganglion cells from induced pluripotent stem cells with improved efficiency and reproducibility. The workflow produced cultures reported to exceed 80% RGC purity and enabled further enrichment to nearly 95%, offering a practical platform for retinal disease modeling while leaving questions of long-term function and therapeutic use open.

• Engineering T-Cell Immunity in Immune-Cold Tumors

  2026-09-25

  He et al. describe a tumor-targeted plasmid that combines LIGHT-mediated immune recruitment and tissue remodeling with tumor-localized anti-CD3 T-cell engagement. In preclinical solid-tumor settings, this coordinated strategy increased antitumor T-cell activity and enhanced checkpoint blockade and CAR-T therapy, while its clinical safety and transferability remain to be established.

• Mouse Toxicology of 5-Aza-2'-deoxycytidine

  2026-09-25

  Momparler and Frith characterized the acute and recovery-phase toxicity of intravenously infused 5-Aza-2'-deoxycytidine in mice, reporting sex-specific LD50 estimates alongside hematologic and tissue effects. The study’s practical contribution is a preclinical safety profile that cautions against treating antileukemic activity and dose-related toxicity as separable when designing Decitabine experiments.

• JWH 133 and Liver Iron Overload Mechanisms

  2026-09-24

  Explore how JWH 133 helps investigate cannabinoid receptor 2 signaling in iron-overloaded liver models. This article connects cell-specific hepcidin and ferroportin mechanisms to practical assay design and the limits of current evidence.

• LTI6426 Sensitizes Myeloma Models to Panobinostat

  2026-09-24

  A preclinical study found that inhibiting protein disulfide isomerase with LTI6426 enhanced low-dose panobinostat activity in proteasome inhibitor-resistant multiple myeloma models. The combination induced an endoplasmic-reticulum-stress-associated transcriptional response, identifying ATF3, DDIT3/CHOP, and DNAJB1 as candidate pharmacodynamic biomarkers—not yet clinically validated markers.

• Propranolol Reprograms Burn-Associated Metabolism

  2026-09-23

  A phase II randomized study examined how propranolol reshapes adipose-tissue metabolism after severe burns. Its metabolomic and lipidomic findings connect beta-blockade with altered energy and nucleotide pathways, a less inflammatory lipid profile, and reduced markers of lipolysis and endoplasmic-reticulum stress.

• Vorinostat and the Next Logic of Cancer Cell Death

  2026-09-23

  Vorinostat is more than a benchmark HDAC inhibitor: it is a translational tool for separating chromatin remodeling, transcriptional disruption, and mitochondrial apoptosis in cancer models.

• DiscoveryProbe Metabolism-related Compound Library

  2026-09-22

  Build metabolism screens that move from enzyme-level activity to cellular and ex vivo validation. This workflow uses the DiscoveryProbe™ collection to investigate lipid remodeling, stress signaling, HMG-CoA reductase inhibition, and metabolism-linked phenotypes without treating a clinical observation as proof of molecular causality.

• Okadaic acid: PP1/PP2A Assay Guidance

  2026-09-22

  Okadaic acid (SKU A4540) provides a nanomolar-range tool for comparing PP2A- and PP1-dependent phosphorylation changes in biochemical and cell-based workflows. It is appropriate for validated phosphatase, apoptosis, and signal-transduction assays, but biochemical IC50 values should not be treated as direct cellular dosing instructions or evidence for non-phosphatase targets.

8010 records 1/534 page Next 12345 下5页 Last page